Theratechnologies Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Theratechnologies stock.
View analyst ratings for Theratechnologies or view top-rated stocks.

Wall Street analysts have given Theratechnologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Theratechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Theratechnologies saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 466,600 shares, an increase of 34.5% from the January 28th total of 346,900 shares. Based on an average daily volume of 533,900 shares, the short-interest ratio is presently 0.9 days. Approximately 0.6% of the shares of the company are sold short.
View Theratechnologies' Short Interest.

Theratechnologies is scheduled to release its next quarterly earnings announcement on Tuesday, April 13th 2021.
View our earnings forecast for Theratechnologies.

Theratechnologies Inc. (NASDAQ:THTX) announced its earnings results on Thursday, February, 25th. The company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). Theratechnologies had a negative trailing twelve-month return on equity of 135.78% and a negative net margin of 37.22%.
View Theratechnologies' earnings history.

Theratechnologies' stock was trading at $2.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, THTX stock has increased by 42.0% and is now trading at $3.11.
View which stocks have been most impacted by COVID-19.

Theratechnologies updated its FY 2020 Pre-Market earnings guidance on Thursday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $65.8-66.1 million.

5 equities research analysts have issued twelve-month target prices for Theratechnologies' shares. Their forecasts range from $2.00 to $11.00. On average, they anticipate Theratechnologies' stock price to reach $7.13 in the next year. This suggests a possible upside of 129.1% from the stock's current price.
View analysts' price targets for Theratechnologies or view top-rated stocks among Wall Street analysts.

Some companies that are related to Theratechnologies include Innoviva (INVA), Zogenix (ZGNX), Omeros (OMER), Arcturus Therapeutics (ARCT), Northwest Biotherapeutics (NWBO), Pliant Therapeutics (PLRX), Protagonist Therapeutics (PTGX), Cassava Sciences (SAVA), Aclaris Therapeutics (ACRS), BioXcel Therapeutics (BTAI), Akero Therapeutics (AKRO), Enanta Pharmaceuticals (ENTA), Trillium Therapeutics (TRIL), Avid Bioservices (CDMO) and Radius Health (RDUS).
View all of THTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX).

Theratechnologies trades on the NASDAQ under the ticker symbol "THTX."

Theratechnologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Worth Venture Partners LLC (0.16%), Renaissance Technologies LLC (0.14%), Fisher Asset Management LLC (0.04%), Inspire Advisors LLC (0.04%), OneAscent Wealth Management LLC (0.01%) and Cambridge Investment Research Advisors Inc. (0.01%).

THTX stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, and Cambridge Investment Research Advisors Inc..

THTX stock was bought by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC, Renaissance Technologies LLC, Inspire Advisors LLC, OneAscent Wealth Management LLC, and Tranquility Partners LLC.

Shares of THTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of THTX stock can currently be purchased for approximately $3.11.

Theratechnologies has a market capitalization of $291.85 million and generates $63.22 million in revenue each year. The company earns $-12,500,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

Theratechnologies employs 42 workers across the globe.

The official website for Theratechnologies is www.theratech.com.

Theratechnologies is headquartered at 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8.

Theratechnologies' mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The company can be reached via phone at 514-336-7800 or via email at [email protected]